Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAIOC9)

Drug Name

Dideazafolate Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glycinamide ribonucleotide formyltransferase (GART)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PELITREXOL	DMR6USG	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
LY309887	DMJPCHK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
10-Formyl-5,8,10-Trideazafolic Acid	DMEBHML	Discovery agent	N.A.	Investigative	[4]
Glycinamide Ribonucleotide	DMW180Y	Discovery agent	N.A.	Investigative	[4]
(10r)-10-Formyl-5,8,10-Trideazafolic Acid	DMVTLF9	Discovery agent	N.A.	Investigative	[4]
10-trifluoroacetyl-DDACTHF	DMEAGI6	Discovery agent	N.A.	Investigative	[5]
Dideazaacyclotetrahydrofolic acid	DM9WU3R	Discovery agent	N.A.	Investigative	[6]
10-CF3C(OH)2-DDACTHF	DMQOUJ7	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glycinamide ribonucleotide formyltransferase (GART)	TTEXB9Z	PUR2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	N10-substituted 5,8-dideazafolate inhibitors of glycinamide ribonucleotide transformylase. J Med Chem. 1987 Jul;30(7):1254-6.
2	Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors. J Clin Oncol (Meeting Abstracts) July 2004 vol. 22 no. 14_suppl 3075.
3	New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer. 1998;78 Suppl 3:1-7.
4	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5	Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase. J Med Chem. 2006 May 18;49(10):2998-3002.
6	Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase. J Med Chem. 2008 Sep 11;51(17):5441-8.